TY - JOUR
T1 - Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica
T2 - A meta-analysis
AU - Ruiz-Gaviria, Rafael
AU - Baracaldo, Ivan
AU - Castañeda, Camilo
AU - Ruiz-Patiño, Alejandro
AU - Acosta-Hernandez, Andres
AU - Rosselli, Diego
N1 - Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Objective Antibodies against water channel protein aquaporin 4 (AQP4) in astrocytes play a role in the etiology and physiopathology of neuromyelitis optica (NMO); detection of this immunoglobulin in serum is highly suggestive of this diagnosis. There are several immunoassays to detect the antibody with different sensitivities and specificities. We conducted a meta-analysis to determine the overall diagnostic accuracy from these tests. Methods We conducted a systematic review in five different electronic databases: Pubmed, Embase, The Cochrane Library, Scopus, Database of Abstracts of Reviews of Effect (DARE) and Lilacs. We included both case control and consecutive enrollment studies that evaluated the performance of the immunoassays in patients with suspected NMO in comparison with the 2006 Wingerchuk diagnostic criteria. Articles were assessed by two different reviewers, who also extracted data. Results 30 studies for three different immunoassays were included in the meta-analysis. To obtain a summary estimate for the sensitivity and specificity with 95% confidence interval a bivariate random effect model was used. The approximated sensitivity for the cell based assay (CBA), the tissue-based assay (TBA) and the ELISA test were 0.76(95% CI 0.67-0.82), 0.59(95% CI 0.50-0.67), and 0.65(95% CI 0.53-0.75) respectively. The mean specificity of the CBA was 0.99 (95% CI 0.97-0.99), TBA 0.98 (95% CI 0.97-0.99) and ELISA 0.97(95% CI 0.96-0.99). Conclusions AQP4 detection in serum with immunoassay is a great tool for the diagnosis of patients with NMO, due to the high specificity, allowing the clinician to differentiate this disease from other neurological conditions that resemble NMO.
AB - Objective Antibodies against water channel protein aquaporin 4 (AQP4) in astrocytes play a role in the etiology and physiopathology of neuromyelitis optica (NMO); detection of this immunoglobulin in serum is highly suggestive of this diagnosis. There are several immunoassays to detect the antibody with different sensitivities and specificities. We conducted a meta-analysis to determine the overall diagnostic accuracy from these tests. Methods We conducted a systematic review in five different electronic databases: Pubmed, Embase, The Cochrane Library, Scopus, Database of Abstracts of Reviews of Effect (DARE) and Lilacs. We included both case control and consecutive enrollment studies that evaluated the performance of the immunoassays in patients with suspected NMO in comparison with the 2006 Wingerchuk diagnostic criteria. Articles were assessed by two different reviewers, who also extracted data. Results 30 studies for three different immunoassays were included in the meta-analysis. To obtain a summary estimate for the sensitivity and specificity with 95% confidence interval a bivariate random effect model was used. The approximated sensitivity for the cell based assay (CBA), the tissue-based assay (TBA) and the ELISA test were 0.76(95% CI 0.67-0.82), 0.59(95% CI 0.50-0.67), and 0.65(95% CI 0.53-0.75) respectively. The mean specificity of the CBA was 0.99 (95% CI 0.97-0.99), TBA 0.98 (95% CI 0.97-0.99) and ELISA 0.97(95% CI 0.96-0.99). Conclusions AQP4 detection in serum with immunoassay is a great tool for the diagnosis of patients with NMO, due to the high specificity, allowing the clinician to differentiate this disease from other neurological conditions that resemble NMO.
KW - Aquaporin 4
KW - Diagnostic test
KW - Immunoassays
KW - Neuromyelitis optica
KW - Sensitivity
KW - Specificity
UR - http://www.scopus.com/inward/record.url?scp=84937432616&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2015.06.003
DO - 10.1016/j.msard.2015.06.003
M3 - Article
C2 - 26195055
AN - SCOPUS:84937432616
SN - 2211-0348
VL - 4
SP - 345
EP - 349
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
IS - 4
ER -